A detailed history of Conning Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Conning Inc. holds 1,488 shares of VRTX stock, worth $704,984. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,488
Previous 1,528 2.62%
Holding current value
$704,984
Previous $621,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

SELL
$407.69 - $446.08 $16,307 - $17,843
-40 Reduced 2.62%
1,488 $621,000
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $3,430 - $4,106
10 Added 0.66%
1,528 $621,000
Q3 2023

Oct 26, 2023

SELL
$338.18 - $362.46 $6,763 - $7,249
-20 Reduced 1.3%
1,518 $527,000
Q2 2023

Jul 21, 2023

SELL
$314.42 - $351.91 $73,888 - $82,698
-235 Reduced 13.25%
1,538 $541,000
Q1 2023

Apr 27, 2023

SELL
$283.23 - $323.1 $5,664 - $6,462
-20 Reduced 1.12%
1,773 $558,000
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $2,286 - $2,571
-8 Reduced 0.44%
1,793 $517,000
Q3 2022

Oct 28, 2022

SELL
$273.83 - $305.53 $27,930 - $31,164
-102 Reduced 5.36%
1,801 $521,000
Q2 2022

Jul 20, 2022

SELL
$234.96 - $292.55 $5,169 - $6,436
-22 Reduced 1.14%
1,903 $536,000
Q1 2022

May 02, 2022

SELL
$221.42 - $260.97 $37,641 - $44,364
-170 Reduced 8.11%
1,925 $502,000
Q4 2021

Jan 27, 2022

SELL
$177.01 - $223.45 $70,626 - $89,156
-399 Reduced 16.0%
2,095 $460,000
Q3 2021

Nov 05, 2021

SELL
$181.39 - $202.99 $107,020 - $119,764
-590 Reduced 19.13%
2,494 $452,000
Q2 2021

Jul 29, 2021

SELL
$187.49 - $221.1 $56,809 - $66,993
-303 Reduced 8.95%
3,084 $622,000
Q1 2021

Apr 23, 2021

SELL
$207.02 - $241.31 $62,106 - $72,393
-300 Reduced 8.14%
3,387 $728,000
Q4 2020

Jan 28, 2021

SELL
$207.01 - $276.09 $3,105 - $4,141
-15 Reduced 0.41%
3,687 $871,000
Q3 2020

Oct 21, 2020

BUY
$255.65 - $303.1 $17,639 - $20,913
69 Added 1.9%
3,702 $1.01 Million
Q2 2020

Aug 07, 2020

SELL
$225.48 - $295.8 $57,271 - $75,133
-254 Reduced 6.53%
3,633 $1.06 Million
Q1 2020

Apr 29, 2020

BUY
$199.77 - $247.81 $1,398 - $1,734
7 Added 0.18%
3,887 $925,000
Q4 2019

Jan 29, 2020

BUY
$166.71 - $223.91 $6,668 - $8,956
40 Added 1.04%
3,880 $850,000
Q2 2019

Jul 25, 2019

SELL
$164.61 - $190.37 $256,626 - $296,786
-1,559 Reduced 28.88%
3,840 $704,000
Q1 2019

Apr 22, 2019

SELL
$163.73 - $194.7 $9,823 - $11,682
-60 Reduced 1.1%
5,399 $993,000
Q4 2018

Jan 29, 2019

SELL
$151.91 - $192.21 $74,435 - $94,182
-490 Reduced 8.24%
5,459 $905,000
Q3 2018

Oct 26, 2018

SELL
$167.73 - $192.74 $30,191 - $34,693
-180 Reduced 2.94%
5,949 $1.15 Million
Q2 2018

Jul 25, 2018

SELL
$145.72 - $169.96 $13,114 - $15,296
-90 Reduced 1.45%
6,129 $1.04 Million
Q1 2018

May 04, 2018

SELL
$151.6 - $177.13 $16,676 - $19,484
-110 Reduced 1.74%
6,219 $1.01 Million
Q4 2017

Jan 30, 2018

SELL
$137.28 - $155.55 $9,609 - $10,888
-70 Reduced 1.09%
6,329 $948,000
Q3 2017

Oct 20, 2017

BUY
$148.13 - $162.24 $947,883 - $1.04 Million
6,399
6,399 $973,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Conning Inc. Portfolio

Follow Conning Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.